A phase II antiemetic combination (COMD) for cisplatin-induced nausea and vomiting.

Abstract

Thirteen patients resistant to high-dose metoclopramide (greater than or equal to 5 emetic episodes in 24 h following chemotherapy) were treated in the subsequent course of CDDP chemotherapy with COMD (chlorpromazine, orphenadrine, metoclopramide, dexamethasone). A statistically significant reduction in the number of vomiting episodes was obtained, and 69% of patients showed a better acceptance of CDDP treatment. Subsequently, the same antiemetic combination was administered to 31 untreated patients receiving CDDP alone for the first time: 67.7% obtained complete protection from vomiting with minimal toxicity. According to our experience, COMD is an efficacious and well-tolerated antiemetic combination in cisplatin-treated patients; however, further studies with larger numbers of patients are required to confirm these preliminary results.

• Authors: F Roila, C Basurto, V Minotti, E Ballatori, M Tonato
• Journal: Cancer chemotherapy and pharmacology (Cancer Chemother Pharmacol) Vol. 18 Issue 1 Pg. 88-9 ( 1986) ISSN: 0344-5704 [Print] Germany
• PMID: 3757163 (Publication Type: Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antiemetics
• Drug Combinations
• chlorpromazine, dexamethasone, metoclopramide, orphenadrine drug combination
• Dexamethasone
• Orphenadrine
• Metoclopramide
• Chlorpromazine

Topics

• Adult
• Aged
• Antiemetics (therapeutic use)
• Chlorpromazine (therapeutic use)
• Dexamethasone (therapeutic use)
• Drug Combinations (therapeutic use)
• Drug Evaluation
• Drug Therapy, Combination
• Female
• Humans
• Male
• Metoclopramide (therapeutic use)
• Middle Aged
• Orphenadrine (therapeutic use)